EMA Accepts Marketing Application for Alvotech's Golimumab Biosimilar, AVT05
核心洞察
The European Medicines Agency (EMA) has accepted Alvotech's Marketing Authorization Application (MAA) for AVT05, a biosimilar candidate to Simponi (golimumab).
AVT05 is intended for the treatment of several chronic inflammatory diseases, potentially offering a more affordable alternative to the reference biologic.
Clinical studies have demonstrated comparable efficacy, safety, and immunogenicity between AVT05 and Simponi in patients with moderate to severe rheumatoid arthritis (搜索).
Alvotech has announced the European Medicines Agency (EMA) acceptance of its Marketing Authorization Application (MAA) for AVT05, a proposed biosimilar to Simponi (golimumab). This marks a significant milestone as it is believed to be the first MAA filing globally for a biosimilar candidate to golimumab. The outcome of the EMA review is expected in the fourth quarter of 2025.
AVT05 is being developed as a biosimilar to golimumab, a biologic TNF-alpha (搜索) inhibitor used to treat various chronic inflammatory diseases, including rheumatoid arthritis (搜索), psoriatic arthritis (搜索), ankylosing spondylitis (搜索), ulcerative colitis (搜索), and Crohn's disease (搜索). These conditions represent a substantial global health burden, and affordable treatment options are highly desirable.
Clinical Trial Data
Alvotech reported positive top-line results from a confirmatory clinical study in April 2024, comparing AVT05 to Simponi in patients with moderate to severe rheumatoid arthritis (搜索). The study assessed efficacy, safety, and immunogenicity, demonstrating comparable outcomes between the biosimilar and the reference product. Furthermore, a pharmacokinetic study in healthy adult participants, announced in November 2023, showed similar pharmacokinetic profiles, safety, and tolerability between AVT05 and Simponi.
Commercialization Strategy
Alvotech and Advanz Pharma (搜索) have an existing commercialization agreement, initially established in February 2023 for AVT23, a proposed biosimilar to Xolair (omalizumab). The partnership expanded in May 2024 to include AVT05, AVT16 (a proposed biosimilar to Entyvio (vedolizumab)), and three additional early-stage biosimilar candidates. This strategic collaboration aims to broaden the availability of biosimilar medicines across various therapeutic areas.
Implications for Patients and Healthcare Systems
If approved, AVT05 could provide a more cost-effective alternative to Simponi, potentially increasing patient access to this important therapy. Biosimilars play a crucial role in reducing healthcare costs and improving the sustainability of healthcare systems by fostering competition in the pharmaceutical market.